Litcius/Paper detail

Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy

Andrea Ferrari, Johannes H. M. Merks, Julia Chisholm, Daniel Orbach, Bernadette Brennan, Soledad Gallego, Max M. van Noesel, Kieran McHugh, Rick R. van Rijn, Mark N. Gaze, Hélène Martelli, Christophe Bergeron, Nadège Corradini, Véronique Minard‐Colin, Gianni Bisogno, Birgit Geoerger, Hubert Caron, Gian Luca De Salvo, Michela Casanova

2020European Journal of Cancer23 citationsDOI

Topics & Concepts

BevacizumabMedicineRhabdomyosarcomaClinical endpointSurgeryChemotherapySoft tissue sarcomaSarcomaConfidence intervalInternal medicineOncologySoft tissueRandomized controlled trialPathologySarcoma Diagnosis and TreatmentAngiogenesis and VEGF in CancerVascular Tumors and Angiosarcomas
Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy | Litcius